4[2]Tokars JI,Miller ER,Alter MJ,et al.National surveillance of dialysis-associated diseases in the United states,1997[J].Semin Dial,2000,13: 75-85.
5[6]Pereira BJ,Snodgrass B,Barber G,et al.Cytokine production during in vitro hemodialysis with new and for maldehyde of Renalin-reprocessed cellulose dialyzers[J].J Am Soc Nephrol,1955,6: 1304-1308.
6[10] Ringoir S: An update on uremic toxins[J]. Kidney Int,1997,52(s62):s2-s4.
7[11] Rosemary O,Brian PS,Richard AW,et al. Maintaining blood compartment volume in dialyzers reprocessed with peracetic acid maintains Kt/V but not β2-microglobulin removal[J]. Am J Kid Dis,1997,30(4):501-506.
8[1] Sethi D, Gower PE.β2-microglobulin levels, dialysis arth-ropathy and the effect of dialyzer membrane[J]. Nephrol Dial Transplant,1988,3:768-772.
9[2] Caverle Y,Simon P,Ang KS,et al. Serum β2-microglobulin levels in hemodialysis uremia depending on permeability of dialysis membranes[J]. Kidney Int,1987,31:229(abstrac).
10[3] Maidment J,Peter SJ. The dialysis prescription: reuse[J]. Am J Nephrol,1996,16:52-59.
